Product image of Icatibant Accord (Icatibant) supplied by GNH India

Icatibant Accord

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Accord (Icatibant)

Icatibant, the active ingredient in Icatibant Accord, is a bradykinin B2 receptor antagonist presented as a 30 mg/0.3 mL subcutaneous solution for injection use. By competitively blocking the bradykinin B2 receptor, it reduces vasodilation and vascular permeability, providing rapid relief of hereditary angioedema attacks caused by C1‑inhibitor deficiency in affected patients.

GNH India supplies Icatibant Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity during global distribution.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Icatibant is used to treat conditions mediated by excessive bradykinin activity, primarily hereditary angioedema.
  • Hereditary angioedema (type I): rapid relief of acute swelling attacks.
  • Hereditary angioedema (type II): rapid relief of acute swelling attacks.
  • Hereditary angioedema (any type) acute attacks: reduces duration and severity of episodes.

How It Works

  • Icatibant acts as a competitive antagonist at the bradykinin B2 receptor. By binding to this receptor, it blocks the actions of bradykinin, preventing the vasodilation and increased vascular permeability that lead to the edema characteristic of hereditary angioedema attacks.

Side Effects

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or erythema: localized skin reddening.
  • Swelling at injection site: transient edema.
  • Nausea: occasional gastrointestinal upset.
  • Headache: mild to moderate headache.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Hypersensitivity reaction: rash, urticaria, or anaphylaxis.
  • Severe hypotension: sudden drop in blood pressure.
  • Angioedema at injection site: extensive swelling.
  • Infection: localized infection of the injection site.
  • Thrombocytopenia: rare decrease in platelet count.
  • Cardiovascular events: rare chest pain or arrhythmia.

Precautions & Warnings

  • Before initiating therapy, clinicians should evaluate patient suitability and monitor for adverse events.
  • Assess patient history: confirm diagnosis of hereditary angioedema before use.
  • Monitor for hypersensitivity: observe for signs of allergic reaction after injection.
  • Avoid in patients with known hypersensitivity: do not administer to individuals allergic to icatibant or excipients.
  • Use with caution in patients on ACE inhibitors: increased bradykinin levels may affect response.
  • Pregnancy and lactation: safety not established; weigh benefits against potential risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant may interact with other medications that influence bradykinin pathways or cardiovascular status.

Major Interactions (Avoid)

  • Concurrent ACE inhibitor therapy: may increase bradykinin levels and reduce efficacy.
  • Co‑administration with other bradykinin B2 antagonists: additive pharmacologic effect unknown.
  • Simultaneous use of injectable biologics: may increase risk of injection‑site reactions.

Moderate Interactions (Monitor Closely)

  • Antihistamines: may mask early signs of hypersensitivity.
  • Diuretics: potential for additive blood‑pressure effects.
  • Estrogen‑containing contraceptives: may alter frequency of angioedema attacks.

Frequently Asked Questions

Icatibant Accord is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients with C1‑inhibitor deficiency. It provides rapid symptom relief by targeting the underlying bradykinin‑mediated swelling.

Icatibant works as a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and increased vascular permeability, which are the primary drivers of edema in hereditary angioedema.

The prescribed dose is determined by the treating physician. Typically, a single 30 mg subcutaneous injection is administered at the onset of an HAE attack, with additional doses allowed according to clinical guidance if the attack persists.

Safety of icatibant during pregnancy and lactation has not been established. It should be used only if the potential benefit justifies any potential risk to the mother or infant, and the decision must be made by a qualified healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams, verifies trade or institutional credentials, and then provides pricing, availability, shipping (including cold‑chain handling where required) and the necessary import documentation.

The primary alternative for HAE attacks is C1‑esterase inhibitor replacement therapy. Icatibant is a small‑molecule B2 receptor antagonist given subcutaneously, whereas C1‑inhibitor concentrates are plasma‑derived or recombinant proteins administered intravenously. Both abort attacks but differ in mechanism, route, and storage requirements.

Store the product at 2–8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use, and discard any solution that appears discolored or contains particles.

Icatibant is delivered as a subcutaneous injection using the supplied prefilled syringe. The injection is given into the abdomen, thigh, or upper arm by a trained healthcare professional or, after proper training, by the patient or caregiver at the first sign of an HAE attack.

Serious adverse reactions include hypersensitivity or anaphylaxis, severe hypotension, and rare cases of extensive angioedema at the injection site. Patients should seek immediate medical attention if they experience difficulty breathing, swelling of the face or throat, or a rapid drop in blood pressure.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with severe cardiovascular disease, uncontrolled hypertension, or those receiving ACE inhibitors, as these conditions may increase the risk of adverse events.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT